SIWA THERAPEUTICS
They founded SIWA in 2006 to develop biological therapies, including their proprietary humanized monoclonal antibody, SIWA 318H, for slowing or reversing the aging process through the removal of SCs. SCs are causally implicated in age-related dysfunction and in degenerative disease. These cells act primarily by secreting substances which interfere with normal functions of other cells; thus, removing them has been shown to improve healthspan and lifespan.
SIWA THERAPEUTICS
Industry:
Biotechnology Therapeutics
Founded:
2006-01-01
Address:
Chicago, Illinois, United States
Country:
United States
Website Url:
http://www.siwatherapeutics.com
Total Employee:
1+
Status:
Active
Contact:
+1 (312) 445-8529
Email Addresses:
[email protected]
Total Funding:
1.63 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Apple Mobile Web Clips Icon WordPress Font Awesome Apache Wordpress Plugins
Current Advisors List
Current Employees Featured
Founder
Official Site Inspections
http://www.siwatherapeutics.com
- Host name: eos.springshosting.net
- IP address: 192.30.131.114
- Location: Colorado Springs United States
- Latitude: 38.9129
- Longitude: -104.7794
- Metro Code: 752
- Timezone: America/Denver
- Postal: 80918
More informations about "SIWA Therapeutics"
Leadership - Siwa Therapeutics
Leadership. Lewis S. Gruber is CEO, Chief Scientific Officer and Co-Founder of SIWA Therapeutics.He is also the named inventor on all of SIWA Therapeutics’ portfolio of more …See details»
SIWA Therapeutics - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number +1 (312) 445-8529 They founded SIWA in 2006 to develop biological therapies, including their proprietary humanized …See details»
Contact – Siwa Therapeutics
[email protected]. Media: [email protected] . Send us a message! Fields marked with an * are required. First Name Last Name Email * Subject Message If you …See details»
SIWA Therapeutics - LinkedIn
SIWA Therapeutics is a privately held preclinical stage biotechnology company that has a monoclonal antibody that targets and destroys senescent cells.See details»
SIWA Therapeutics Company Profile | Management and …
Www.siwatherapeutics.com . Contact Information. Headquarters. Chicago, Illinois, United States (312) 445-8529. SIWA Therapeutics Profile and History . SIWA Therapeutics, Inc. is focused …See details»
SIWA Therapeutics - Overview, News & Similar companies
Feb 23, 2022 SIWA Therapeutics Announces Promising Results in New Pancreatic Cancer Study SIWA's Proprietary Humanized Monoclonal Antibody, SIWA318H, is Efficacious in an …See details»
SIWA Therapeutics - Overview, Competitors, and Employees
They founded SIWA in 2006 to develop biological therapies, including their proprietary humanized monoclonal antibody, SIWA 318H, for slowing or reversing the aging process through the …See details»
SIWA Therapeutics - Products, Competitors, Financials, Employees ...
Headquarters Location. 400 E. Randolph Suite 3911. Chicago, Illinois, 60601, United States. 312-543-7172See details»
SIWA Therapeutics - Company Profile - Tracxn
Aug 27, 2024 SIWA Therapeutics is developing a monoclonal antibody that targets and destroys senescent cells. The company lead product SIWA 318, targets a naturally-occurring …See details»
SIWA Therapeutics - Company Profile & Staff Directory - ContactOut
SIWA Therapeutics is a privately held preclinical stage biotechnology company that has a monoclonal antibody that targets and destroys senescent cells. Our current therapeutic focus …See details»
New antibody shows strong potential against pancreatic cancer
Oct 12, 2023 Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based nonprofit organization dedicated to conducting groundbreaking research with life-changing …See details»
SIWA Therapeutics - Craft
SIWA Therapeutics $1.6 m in total funding,. See insights on SIWA Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
SIWA Therapeutics - PitchBook
SIWA Therapeutics General Information Description. Operator of a pre-clinical stage research entity intended to emphasize a monoclonal antibody that targets and destroys cancerous cells.See details»
SIWA Therapeutics - VentureRadar
SIWA Therapeutics, Inc. is a pre-clinical stage company with: A first-in-class humanized monoclonal antibody (“mAb”), SIWA 318H, that selectively... ... Find out ...See details»
Siwa Therapeutics - Company info. interviews, news
SIWA Therapeutics is a privately held preclinical stage biotechnology company that has a monoclonal antibody that targets and destroys senescent cells.See details»
Partners – Siwa Therapeutics
For more information, please contact us at [email protected]. About Us. SIWA’s 318H monoclonal antibody targets a biomarker on cancer cells and senescent cells. Our initial …See details»
SIWA Therapeutics To Participate in September Investor Conferences
Sep 16, 2020 More information is available at www.siwatherapeutics.com. Contacts. Ellyn Caruso | [email protected] Sally Leaf | [email protected] 312-854-7079 Release Summary.See details»
SIWA Therapeutics Announces Promising Results in New …
Mar 14, 2022 Both the SIWA318H high dose and low dose treatment groups showed significant anti-tumor activity in a PSN1 human pancreatic cancer mouse xenograft tumor model by …See details»
News - Siwa Therapeutics
CHICAGO, Feb. 24, 2022 /PRNewswire/ -- SIWA THERAPEUTICS, INC, which has developed SIWA318H, a proprietary monoclonal antibody that has caused complete remission of …See details»